SuperworthMetagenomi Therapeutics EPS MGX
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$2.49
- Latest quarter, Q2 FY26
- −$0.73
- Fiscal year 2025
- −$2.37
Metagenomi Therapeutics' earnings per share was −$2.49 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.73.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.37 | n/a |
| FY2024 | −$2.62 | n/a |
| FY2023 | −$20.05 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.73 | n/a | −$2.49 | |
| Q1 FY26 | −$0.61 | n/a | −$2.30 | |
| Q4 FY25 | −$0.60 | n/a | −$2.37 | |
| Q3 FY25 | −$0.55 | n/a | −$2.40 | |
| Q2 FY25 | −$0.54 | n/a | −$2.36 | |
| Q1 FY25 | −$0.68 | n/a | −$2.11 | |
| Q4 FY24 | −$0.63 | n/a | −$2.62 | |
| Q3 FY24 | −$0.51 | n/a | −$7.66 | |
| Q2 FY24 | −$0.29 | n/a | −$12.97 | |
| Q1 FY24 | −$1.19 | n/a | −$16.50 | |
| Q4 FY23 | −$5.67 | n/a | −$20.05 | |
| Q3 FY23 | −$5.82 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Metagenomi Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MGXMetagenomi Therapeutics | −$2.49 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Metagenomi Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.